PGS Sample Set (PSS): PSS001001

Phenotype All individuals were carriers of a pathogenic or likely pathogenic variant (MYBPC3 truncating variant, MYBPC3 non-truncating variant, MYH7 variant, MYL2 variant, other genetic variant). The primary outcome of maximal left ventricular wall thickness is defined as maxLVWT indexed to body surface area (BSA) on last available CMR or TTE prior to septal reduction therapy and cardiac transplantation. LVWT from CMR used whenever available unless TTE performed more than 5 years after last CMR.
Sample Ancestry Not reported

Sample Numbers

Total number
322 individuals
Number of Cohort(s) 1


Cohort Short Name Cohort Full Name Previous/other/additional names (e.g. sub-cohorts)
ERSPC European Randomised Study of Screening for Prostate Cancer